Loading…
Addex Therapeutics Ltd is projected to rise to $7.12 by 2027, a +4% move from its current price of $6.82. ADXN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $6.63 | $6.82 | $7.02 | +0.06% |
| May 30 | $6.55 | $6.83 | $7.11 | +0.11% |
| May 31 | $6.50 | $6.83 | $7.18 | +0.17% |
| Jun 1 | $6.45 | $6.84 | $7.24 | +0.23% |
| Jun 2 | $6.41 | $6.84 | $7.30 | +0.29% |
| Jun 3 | $6.37 | $6.84 | $7.35 | +0.34% |
| Jun 4 | $6.34 | $6.85 | $7.39 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $6.34 | $6.85 | $7.39 | +0.40% |
| Week 2 | $6.17 | $6.87 | $7.66 | +0.80% |
| Week 3 | $6.04 | $6.90 | $7.88 | +1.20% |
| Week 4 | $5.94 | $6.93 | $8.08 | +1.61% |
| Week 5 | $5.86 | $6.96 | $8.26 | +2.01% |
| Week 6 | $5.79 | $6.99 | $8.43 | +2.42% |
| Week 7 | $5.72 | $7.01 | $8.59 | +2.83% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Addex Therapeutics Ltd is a healthcare company that discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes.
Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. It also develops ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM); and GABAB PAM for the treatment of pain, anxiety, addiction, cough, and overactive bladder.
The company has license and collaboration agreements with Janssen Pharmaceuticals Inc. for the mGlu2 PAM compounds and with Indivior PLC for the discovery, development, and commercialization of novel GABAB PAM compounds for CNS diseases. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Addex Therapeutics Ltd (ADXN) is a healthcare company with a current price of $6.83, a market capitalization of $8.65M, and a rank of 5192.
The 30-day forecast suggests a neutral near-term stance, with 2026 min $5.66, avg $6.83, max $8.86 and an ROI of 0%. The sentiment for the year is NEUTRAL.
Longer-term, the multi-year forecast shows bullish upside, with 2030 avg $9.75 and 42.7% ROI; 2040 avg $17.99 and 163.4% ROI; and 2050 avg $33.17 and 385.6% ROI, indicating substantial potential upside over the horizon.
A major floor 17.0% below — a decisive break under it would weaken the trend.
The nearest floor, 10.0% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 22.1% above — clearing it would confirm fresh momentum.
Key ADXN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ADXN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.83 | Sell | $6.83 | Sell |
| MA 10 | $6.85 | Sell | $6.84 | Sell |
| MA 20 | $6.88 | Sell | $6.83 | Sell |
| MA 50 | $6.64 | Buy | $6.86 | Sell |
| MA 100 | $7.15 | Sell | $7.13 | Sell |
| MA 200 | $7.86 | Sell | $7.57 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.98 | Neutral |
| Stoch RSI (14) | 28.92 | Neutral |
| CCI (20) | -49.10 | Neutral |
| Williams %R (14) | -61.29 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -0.29 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 38.71 | Neutral |
| TRIX (15) | 0.09 | Buy |
| Awesome (5,34) | -0.00 | Sell |
| Ultimate (7,14,28) | 50.07 | Neutral |
| Momentum (10) | 0.12 | Buy |
| Aroon Osc (25) | -8.00 | Sell |
| Hull MA (9) | 6.81 | Buy |
| ADX (14) | 4.90 | Neutral |
| ATR (14) | 0.16 | Info |
The near-term technical picture is NEUTRAL, with RSI14 at 50. The SMA50 is $6.64 and the SMA200 is $7.87, suggesting price hovering around key averages.
Support is indicated at $6.14 and resistance at $7.20, framing a modest range for the next setup. The 30-day range runs from $5.58 to $8.36, highlighting the current volatility band around the price level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.66 | $6.82 | $8.88 | 0% | Neutral | |
| $5.61 | $7.12 | $9.59 | +4% | Neutral | |
| $5.86 | $7.65 | $10.70 | +12% | Neutral | |
| $6.52 | $8.72 | $12.57 | +28% | Bullish | |
| $7.33 | $10.02 | $14.80 | +47% | Bullish | |
| $8.41 | $11.73 | $17.71 | +72% | Bullish | |
| $8.22 | $11.68 | $17.98 | +71% | Bullish | |
| $7.69 | $11.12 | $17.43 | +63% | Bullish | |
| $8.38 | $12.31 | $19.62 | +81% | Bullish | |
| $8.32 | $12.43 | $20.11 | +82% | Bullish | |
| $12.02 | $19.30 | $33.29 | +183% | Bullish | |
| $19.87 | $36.19 | $68.52 | +431% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $5.66 | $6.82 | $8.01 | +0.00% |
| June 2026 | $5.91 | $6.95 | $8.37 | +1.84% |
| July 2026 | $6.05 | $7.18 | $8.78 | +3.43% |
| August 2026 | $5.90 | $7.05 | $8.71 | -1.84% |
| September 2026 | $5.72 | $6.87 | $8.57 | -2.57% |
| October 2026 | $5.82 | $7.04 | $8.84 | +2.40% |
| November 2026 | $5.88 | $7.14 | $9.04 | +1.51% |
| December 2026 | $5.72 | $6.97 | $8.88 | -2.42% |
Click any year to see its month-by-month ADXN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ADXN price prediction for 2026 points to an average of $6.82 (low $5.66, high $8.88) — a potential gain of 0% on today's $6.82. Price action looks broadly range-bound.
In 2027, ADXN is projected to trade between $5.61 and $9.59, averaging $7.12 — a potential gain of +4% from today's $6.82. That is up +4% on the projected 2026 average. A consolidation phase looks the most probable path here.
Addex Therapeutics Ltd's 2028 outlook centres on $7.65, within a $5.86 to $10.70 range. That is up +7% on the projected 2027 average. That marks a +12% change versus current levels. Price action looks broadly range-bound.
By 2029, ADXN could reach as high as $12.57, with a base case around $8.72 and support toward $6.52 — roughly +28% from $6.82. Buyers look set to stay in control over this stretch.
Expect ADXN to range from $7.33 to $14.80 through 2030. The $10.02 average target implies a +47% move from current prices. That is up +15% on the projected 2029 average. Momentum favours further upside here.
The ADXN price prediction for 2031 points to an average of $11.73 (low $8.41, high $17.71) — a potential gain of +72% on today's $6.82. Buyers look set to stay in control over this stretch.
In 2032, ADXN is projected to trade between $8.22 and $17.98, averaging $11.68 — a potential gain of +71% from today's $6.82. That is 0% versus the projected 2031 average. Momentum favours further upside here.
Addex Therapeutics Ltd's 2033 outlook centres on $11.12, within a $7.69 to $17.43 range. That is -5% versus the projected 2032 average. That marks a +63% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, ADXN could reach as high as $19.62, with a base case around $12.31 and support toward $8.38 — roughly +81% from $6.82. Momentum favours further upside here.
Expect ADXN to range from $8.32 to $20.11 through 2035. The $12.43 average target implies a +82% move from current prices. That is up +1% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The ADXN price prediction for 2040 points to an average of $19.30 (low $12.02, high $33.29) — a potential gain of +183% on today's $6.82. Momentum favours further upside here.
In 2050, ADXN is projected to trade between $19.87 and $68.52, averaging $36.19 — a potential gain of +431% from today's $6.82. That is up +88% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in ADXN today (≈ 146.627566 ADXN) could be worth
$5,306.37
+$4,306.37 (+431%) by 2050 · US Dollar
Based on the average projected ADXN price of $36.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ADXNwould be worth at today's price.
$1,000 invested in ADXN on May 27, 2025 (≈ 119.047624 ADXN) would be worth
$811.9
-$188.1 (-18.8%) today · 0.81× · US Dollar
Based on a ADXN entry price of $8.4 vs. today's $6.82.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.78 | $1,005.9 | +0.6% |
| 1 month ago | $6.59 | $1,034.9 | +3.5% |
| 3 months ago | $6.99 | $975.68 | -2.4% |
| 6 months ago | $7.66 | $889.76 | -11.0% |
| 1 year ago | $8.4 | $811.9 | -18.8% |
| All time (5.0y) ago | $203.6 | $33.5 | -96.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ADXN forecast.
Our base-case forecast reaches $14.00 around 2040.
Implied market cap at $14.00: $17.72M
Over the multi-year horizon, the forecast turns bullish from 2029 onward with steadily rising expectations. In 2029 the avg is $8.36 and the ROI is 22.5%, with a bullish sentiment.
By 2030 the average target climbs to $9.75 (ROI 42.7%), and by 2040 it rises to $17.99 (ROI 163.4%), with continued bullish sentiment. The ultimate 2050 target sits at an average of $33.17 (ROI 385.6%), with a bullish outlook.
These estimates illustrate meaningful upside potential but are not guarantees; actual results may differ as market conditions and company fundamentals evolve.
Tap a question to reveal the answer.
The forecast shows avg $9.75 with min $7.05 and max $14.58; ROI 42.7%, sentiment BULLISH.
Forecasts project growth from a current price of $6.83 toward higher averages, with 2029 avg $8.36, 2030 avg $9.75, 2040 avg $17.99, and 2050 avg $33.17; ROI reaches up to 385.6% by 2050; sentiment turns BULLISH in later years.
Yes—the max forecast in 2050 is $64.20 with ROI 385.6%.
The current price is $6.83.
The long-term forecast shows 2050 average $33.17 and max $64.20 with ROI 385.6%; 2040 average $17.99; 2030 average $9.75, with overall bullish sentiment in the later years.
Addex Therapeutics Ltd Community Discussion
0Share your Addex Therapeutics Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.